EE-drospirenone-levomefolate calcium versus EE-drospirenone + folic acid: folate status during 24 weeks of treatment and over 20 weeks following treatment cessation

Konstanze Diefenbach¹
Dietmar Trummer¹
Frank Ebert¹
Michael Lissy²
Manuela Koch²
Beate Rohde¹
Hartmut Blode³

¹Bayer HealthCare Pharmaceuticals, Berlin, Germany; ²Nuvisan GmbH, Neu-Ulm, Germany; ³Bayer HealthCare Pharmaceuticals Global R&D Center, Beijing, People’s Republic of China

Background: Adequate folate supplementation in the periconceptional phase is recommended to reduce the risk of neural tube defects. Oral contraceptives may provide a reasonable delivery vehicle for folate supplementation before conception in women of childbearing potential. This study aimed to demonstrate that a fixed-dose combination of an oral contraceptive and levomefolate calcium leads to sustainable improvements in folate status compared with an oral contraceptive + folic acid.

Methods: This was a double-blind, randomized, parallel-group study in which 172 healthy women aged 18–40 years received ethinylestradiol (EE)-drospirenone-levomefolate calcium or EE-drospirenone + folic acid for 24 weeks (invasion phase), and EE-drospirenone for an additional 20 weeks (folate elimination phase). The main objective of the invasion phase was to examine the area under the folate concentration time-curve for plasma and red blood cell (RBC) folate, while the main objective of the elimination phase was to determine the duration of time for which RBC folate concentration remained ≥ 906 nmol/L after cessation of EE-drospirenone-levomefolate calcium.

Results: Mean concentration-time curves for plasma folate, RBC folate, and homocysteine were comparable between treatment groups during both study phases. During the invasion phase, plasma and RBC folate concentrations increased and approached steady-state after about 8 weeks (plasma) or 24 weeks (RBC). After cessation of treatment with levomefolate calcium, folate concentrations decreased slowly. The median time to RBC folate concentrations falling below 906 nmol/L was 10 weeks (95% confidence interval 8–12 weeks) after cessation of EE-drospirenone-levomefolate calcium treatment. Plasma and RBC folate levels remained above baseline values in 41.3% and 89.3% of women, respectively, at the end of the 20-week elimination phase.

Conclusion: Improvements in folate status were comparable between EE-drospirenone-levomefolate calcium and EE-drospirenone + folic acid. Plasma and RBC folate levels remained elevated for several months following cessation of treatment with EE-drospirenone-levomefolate calcium.

Keywords: drospirenone, ethinylestradiol, folic acid, levomefolate calcium, neural tube defect, oral contraception

Introduction
Folate is the generic name for many different forms of this water-soluble vitamin, which include, among others, L-5-methyltetrahydrofolate (L-5-methyl-THF) and
folic acid. Folates are essential for DNA and protein synthesis and, hence, cell division. Low folate levels are known to be linked to neural tube defects.

Neural tube defects are a complex group of congenital malformations that occur as a result of incomplete or incorrect closure of the neural tube (e.g., anencephaly and spina bifida) during the early stages of pregnancy, often before a woman knows she is pregnant. While the etiology of neural tube defects remains poorly understood, the Medical Vitamin Research Council study published in 1991 provided supportive evidence that an increased folate status is associated with reduced risk of neural tube defects, and in 1995 a quantitative relationship between reduction in risk of neural tube defects and red blood cell (RBC) folate levels was established by Daly et al. An RBC folate concentration ≥ 906 nmol/L was shown to be associated with a very low risk of neural tube defects (0.8 per 1000 births).

A number of initiatives have been undertaken to improve folate status among women of childbearing potential, including educational campaigns, food fortification programs, and policies to encourage folic acid supplementation during the periconceptional period (ie, both before and during the initial weeks of pregnancy). Current recommendations in the US and Europe specify that all women planning or capable of pregnancy should take folic acid supplements at doses of 0.400 mg/day (0.400–0.800 mg/day in the US), commencing at least one month before conception. Indeed, there is now a large body of evidence to suggest that the occurrence or recurrence of neural tube defects can be dramatically reduced if women use folic acid supplements both before and during the initial weeks of pregnancy.

However, initiatives to improve folate status among women of childbearing potential have, to date, had unsatisfying results. Four studies that assessed the effects of periconceptional folic acid usage before and after the introduction of public folic acid awareness campaigns in the UK, The Netherlands, and Australia showed post-campaign rates of folic acid use did not exceed 50%. In the US, data from the National Health and Nutrition Examination Survey showed that only 24% of nonpregnant women of childbearing potential were consuming the recommended intake of folic acid. For example, levomefolate calcium is less likely to mask symptoms of vitamin B₁₂ deficiency, which is a concern with folic acid supplementation. In addition, there have been concerns about the presence of unmetabolized folic acid in the peripheral circulation; these would be alleviated with levomefolate calcium.

This paper outlines findings from a long-term two-phase study comparing the fixed-dose oral contraceptive formulation EE 0.030 mg–drospirenone 3 mg–levomefolate calcium 0.451 mg with the free combination of oral contraceptive and equimolar folic acid with respect to folate status during 24 weeks of folate treatment and 20 weeks of follow-up without folate intake in healthy women of childbearing potential.

Materials and methods

Study design

This was a randomized, double-blind, double-dummy (ie, throughout treatment, all women received both a tablet and a capsule, one of which was active and one of which was placebo, depending on the treatment group), parallel-group, single-center (Nuvisan GmbH, Neu-Ulm, Germany) study conducted between December 2006 and January 2008. The study was performed in accordance with the ethical principles stipulated by the Declaration of Helsinki and the International Conference on Harmonization/Good Clinical Practice. The study was approved by an independent ethics committee/institutional review board (Ethik-Kommission der Bayerischen Landesärztekammer, München, Germany). All women provided written informed consent prior to study entry. The study was divided into two phases, ie, a 24-week folate invasion phase followed by a 20-week folate elimination phase.
Study participants
Healthy women aged 18–40 years (inclusive) desiring contraception were eligible for inclusion. Participants were selected from the local population in accordance with inclusion and exclusion criteria. At screening, women were required to have plasma vitamin B$_{12}$ concentrations $\geq$ 110 pmol/L and RBC folate levels $> 317$ nmol/L and $< 906$ nmol/L. Smokers were permitted, if they were aged between 18 and 30 years. Exclusion criteria included the usual contraindications for combined oral contraceptive use and: any disease or condition that could compromise the pharmacokinetics of the study medication; any disease or condition that could interfere with conduct of the study or interpretation of its results; intake within 4 weeks prior to study start of any drug known to induce or inhibit liver enzymes; current treatment with any medications that have the potential to interfere with folate metabolism (eg, methotrexate, trimethoprim, antacids, or antiepileptic drugs); or regular consumption of folic acid in vitamin supplements or pharmaceuticals during the preceding 4 months.

Study treatments
The treatment schedule is shown in Figure 1. For the 24-week (six-cycle) invasion phase, women were randomized in a 1:1 ratio to EE 0.030 mg–drospirenone 3 mg–levomefolate calcium 0.451 mg (equivalent to L-5-methyl-THF 0.416 mg) or EE 0.030 mg–drospirenone 3 mg + folic acid 0.400 mg (equimolar to levomefolate calcium 0.451 mg).

Women in the levomefolate calcium group received a tablet containing EE 0.030 mg–drospirenone 3 mg–levomefolate calcium 0.451 mg and a placebo capsule once daily for 21 days, followed by a tablet containing levomefolate...
calcium 0.451 mg only and a placebo capsule for 7 days. In the folic acid group, women took a tablet containing EE 0.030 mg–drospirenone 3 mg and a capsule containing folic acid 0.400 mg once daily for 21 days, followed by a placebo tablet and a folic acid capsule once daily for 7 days. These cyclic regimens were administered six times, ie, for 24 weeks. To maintain blinding, hormone tablets (with or without levomefolate calcium) and placebo tablets were identical in appearance, as were folic acid capsules and placebo capsules.

In the subsequent elimination phase, both groups received EE 0.030 mg – drospirenone 3 mg for a further five cycles (20 weeks). During the elimination phase, each cycle consisted of once-daily hormone treatment for 21 consecutive days, followed by a tablet-free interval of 7 days.

All study medication was provided in identical blister packs to maintain blinding. During the course of the study, women were not allowed to take vitamin supplements or any medications that contained folate or interacted with folate absorption, metabolism, or excretion.

Study assessments

For the determination of plasma and RBC folate, homocysteine and plasma folate metabolites, fasting venous blood samples were collected in plasma tubes coated with lithium-heparin. Samples were collected by trained staff and analyzed at a central laboratory.

Baseline levels

Plasma folate, RBC folate, and plasma homocysteine levels at baseline (ie, at the start of the invasion phase) were determined on three separate occasions (minimum of 5 days apart including one weekend) before any study medication was received. The median of the pretreatment levels was taken to represent the respective individual baseline values.

Plasma and RBC folate levels

Samples were collected at baseline and at biweekly intervals after the start of treatment and were used to determine plasma and whole blood folate levels. Aliquots of whole blood were lyzed with freshly prepared 1% ascorbic acid (1:10 dilution), vortexed, and incubated for 30 minutes in the dark before storage at approximately −80°C until analysis. The remaining whole blood sample was centrifuged to obtain plasma, which was separated and stored frozen at approximately −80°C until analysis.

Plasma and whole blood folate concentrations were determined using a validated microbiologic assay at Toegpast Natuurwetenschappelijk Onderzoek (Netherlands Organisation for Applied Scientific Research), Zeist, The Netherlands. Folate concentrations were calculated using an appropriate calibration curve, with folic acid as a reference (range 25–500 ng/mL for whole blood folate and 1–20 ng/mL for plasma folate). Each plate also included a World Health Organization folate standard control.

Based on the results of quality control sample analyses, precision was deemed to be 5%–18% in plasma and 8%–9% in whole blood, and accuracy was 97%–107% in plasma and 100%–104% in whole blood. RBC folate concentrations were calculated using the following equation (where hematocrit is given as a percentage of whole blood volume):

\[
\text{RBC folate} = \frac{\text{[Whole blood folate} \times 100]}{\text{[Plasma folate} \times (100 - \text{Hematocrit})]} - \frac{\text{Hematocrit}}{100}
\]

For RBC folate, validation rules were put in place to control for unusually high whole blood folate levels (which were deemed to be due to incorrect dilution). Samples with either folate concentrations > 120% of the upper limit of the calibration curve or hematocrit values outside the usual intraindividual variability were deemed invalid.

Plasma homocysteine

Samples were collected at baseline and then every 2 weeks. Plasma was separated by centrifugation at 4°C and stored frozen at approximately −20°C until analysis. Homocysteine concentrations were determined by fluorescence polarization immunoassay using the Abbott Axsym analyzer, (Abbott Diagnostics, Lake Forest, IL, USA) a method that shows good accuracy and precision.\(^{30}\)

Plasma folate metabolites

The main circulating folate metabolites [folic acid, tetrahydrofolate (THF), 5-methyl-THF, 5-formyl-THF/10-formyl-THF, and 5,10-methenyl-THF] were determined in plasma prior to treatment (baseline) and at week 12 and week 24 of treatment. The dihydrofolate metabolite was not analyzed because of its known instability and conversion to folic acid. In addition, no discrimination between 5-formyl-THF and 10-formyl-THF was possible due to the known interconversion of 10-formyl-THF to 5-formyl-THF.\(^{31}\)

Plasma was obtained by centrifugation and stored frozen at approximately −80°C before analysis. Plasma folate metabolites were determined using a validated liquid chromatography-mass spectrometry method, which was characterized as semiquantitative because the acceptance criteria for precision and accuracy were set at 50% (based on quality
The lower level of quantification was as follows for each of the metabolites: folic acid, 3.398–3.710 nmol/L; L-5-methyl-THF, 3.325–3.680 nmol/L; 5-formyl-THF/10-formyl-THF, 1.105–1.260 nmol/L; THF, 3.447–3.539 nmol/L; and 5,10-methenyl-THF, 1.052–1.284 nmol/L.

**Compliance**

Compliance was assessed from participants’ recordings of tablet intake in diaries along with the return of all unused study medication and empty blister packs at each visit.

**Nutritional intake**

To evaluate dietary folate intake, subjects completed a standardized food questionnaire provided by the University of Bonn. The prospective questionnaire was completed for 3 days at admission and at the end of weeks 8, 16, and 24.

**Safety**

Safety was assessed in the full analysis set, which comprised all women who were treated with at least one dose of the study drug, and for whom at least one clinical observation after the start of treatment was available. Evaluations included physical and gynecologic examinations, assessment of vital signs, cervical smear tests, laboratory testing, and monitoring of adverse events. Adverse events that occurred during the study were coded using the Medical Dictionary for Regulatory Activities and assessed by intensity, seriousness, pattern, and relationship to study medication or study conduct (related [possible, probable, and definite]/not related [none, unlikely]). Safety outcomes are presented separately for the invasion phase and elimination phase.

**Statistical analyses and power calculations**

The objectives were different for the invasion and elimination phases of the study.

**Invasion phase**

The primary objective of the invasion phase of this study was to examine whether EE-drospirenone-levomefolate calcium and EE-drospirenone + folic acid produce similar plasma and similar RBC folate exposures (as measured by the area under the folate concentration-time curve over 24 weeks \( \text{AUC}_{(0-24 \text{ weeks})} \) for plasma and RBC folate). These values were chosen as primary variables because, unlike selected individual time points, they integrate changes in these variables over the complete folate treatment period and, thus, provide a more stable parameter for comparison between study groups.

The means of \( \text{AUC}_{(0-24 \text{ weeks})} \) values on the log scale were estimated using an analysis of variance model with treatment as a factor. Two-sided 90% confidence intervals (CIs) for the test (EE-drospirenone-levomefolate calcium) to reference (EE-drospirenone + folic acid) geometric mean ratio of the \( \text{AUC}_{(0-24 \text{ weeks})} \) were calculated for plasma and RBC folate exposure to assess whether they were contained within the limits for bioequivalence (range 80%–125%). Plasma and RBC folate \( \text{AUC}_{(0-24 \text{ weeks})} \) values, uncorrected or corrected for baseline folate concentrations, were analyzed with inferential statistical methods using the per protocol set, which consisted of all treated women who did not present any major protocol deviations.

Other variables assessed during the invasion phase included change in homocysteine levels between baseline and 24 weeks, and plasma folate metabolite patterns at baseline and at 12 and 24 weeks. All secondary variables were analyzed descriptively. Absolute values and change from baseline in plasma folate, RBC folate, and homocysteine levels were also assessed using descriptive statistics.

**Elimination phase**

The main objective of the elimination phase of this study was to determine the duration of time for which RBC folate concentration remained ≥ 906 nmol/L after cessation of folate treatment in women who received EE-drospirenone-levomefolate calcium during the 24-week invasion phase. The duration that RBC folate concentrations were ≥ 906 nmol/L was calculated using the Kaplan–Meier estimator including the two-sided 95% CI for the median time taken for RBC folate concentration to fall below 906 nmol/L. These analyses were undertaken using the per protocol set.

Secondary variables in the elimination phase were assessed in both treatment groups using descriptive statistics and included: mean concentrations, mean changes from baseline, and mean changes from the end of the folate invasion phase (week 24) for plasma folate, RBC folate, and homocysteine at biweekly time points, the proportion of women with RBC and plasma folate levels below their median baseline (prefolate treatment) level, and the proportion of women with homocysteine levels above their median baseline (prefolate treatment) level at biweekly time points from weeks 26–44.

**Sample size**

Taking into account the special design as a long-term bioequivalence study, scheduling a high number of visits with...
blood testing over 24 weeks (the period on which the sample size calculation was based), it was expected that the dropout rate in this study would be higher than that observed in other contraceptive studies. Assuming that 37% of participants would not be included in the per protocol set and that the true ratio of test-to-reference AUC\(_{(0-24\text{ weeks})}\) was 110%, then enrollment of 86 women per treatment group (172 women overall) was required to achieve bioequivalence (limits of 80%–125%) with 90% power. Based on additional analyses of previously published data,\(^\text{24}\) a precision of 0.24 standard deviations of difference on the log-scale was assumed. Although the determination of sample size was based on plasma folate, no adjustment of sample size after inclusion of RBC folate as the primary endpoint was considered necessary because both primary endpoints were expected to be highly correlated.

**Results**

Overall, 235 women were screened, of whom 172 (EE-drospirenone-levomefolate calcium, \(n=86\); EE-drospirenone + folic acid, \(n=86\)) were randomized to treatment. Of the 63 women who were excluded, 46 did not meet the inclusion criteria (three due to low vitamin \(B_12\) levels; none of the women were excluded due to low RBC folate levels), eight withdrew consent, eight were excluded for logistical reasons (ie, the study dates conflicted with planned holidays; these patients were classified as screening failures), and one was excluded because blood sampling was not possible. Women who received study medication and had at least one clinical observation after the start of treatment were included in the full analysis set. Over 44 weeks (both the invasion and elimination phases), 12 women prematurely discontinued the study medication (Figure 2). Major protocol deviations

![Figure 2 Disposition of women throughout the study.](image)

**Abbreviations:** drsp, drospirenone; EE, ethinylestradiol.
(all of which were due to missing valid data) were noted in 11 women in each treatment group. Analysis of the primary variables was performed in 150 women (EE-drospirenone-levomefolate calcium, n = 75; EE-drospirenone + folic acid, n = 75) who showed no major protocol deviations and comprised the per protocol set.

All study participants were Caucasian with a mean age of 27.7 (range 18–40) years. Baseline and demographic characteristics for the per protocol set are reported in Table 1 and were comparable with those in the full analysis set (data not shown). Compliance was high in both treatment groups over 44 weeks (11 cycles); the range of means was 27.6–28.1 tablets/capsules per 28-day cycle. Nutrition assessments were available for 150 women. Mean total dietary folate intake was not substantially different at the four assessment time points (range 0.176 ± 0.070 to 0.209 ± 0.196 mg/day).

### Plasma and RBC folate exposure during the invasion phase

The geometric mean AUC\(_{(0–24\text{ weeks})}\) for plasma and RBC folate were generally comparable following treatment with EE-drospirenone-levomefolate calcium and EE-drospirenone + folic acid (baseline-uncorrected and baseline-corrected values, Table 2). In both treatment groups, variability was higher for baseline-corrected values of AUC\(_{(0–24\text{ weeks})}\) for plasma and RBC folate. The geometric mean ratios (EE-drospirenone-levomefolate calcium versus EE-drospirenone + folic acid) for baseline-uncorrected and baseline-corrected plasma AUC\(_{(0–24\text{ weeks})}\) were 114% (two-sided 90% CI 107%–121%) and 114% (two-sided 90% CI 105%–117%), respectively. Exposure was similar between treatments using bioequivalence criteria (defined as two-sided 90% CI limits of 80%–125%); corresponding geometric mean ratios for baseline-uncorrected and baseline-corrected RBC folate AUC\(_{(0–24\text{ weeks})}\) were 111% (two-sided 90% CI 105%–117%) and 118% (two-sided 90% CI 109%–127%), respectively.

### Plasma and RBC folate concentrations

#### Invasion phase

The mean concentration-time curves for plasma folate and RBC folate during the invasion phase were similar between EE-drospirenone-levomefolate calcium and EE-drospirenone + folic acid groups; however, the concentrations of both plasma and RBC folate were slightly higher with EE-drospirenone-levomefolate calcium (Figures 3 and 4).

Plasma folate levels increased from baseline, approaching a plateau after about 8 weeks in both treatment groups. Mean plasma folate concentrations increased in a cyclic pattern, and the highest plasma folate concentrations were reached at week 22 for both treatments (Figure 3). At week 24 of treatment, mean values were 49.9 ± 15.5 nmol/L for EE-drospirenone-levomefolate calcium and 43.3 ± 13.3 nmol/L for EE-drospirenone + folic acid.

For both treatments, RBC folate concentrations increased (Figure 4), reaching the highest mean concentrations (1361 ± 322 nmol/L for EE-drospirenone-levomefolate calcium and 1207 ± 217 nmol/L for EE-drospirenone + folic acid) at week 24. After 24 weeks of treatment, 95% of women had RBC levels ≥ 906 nmol/L, the level associated with a very low risk of neural tube defects.³ Mean RBC folate levels of ≥ 906 nmol/L were reached after around 8 weeks of treatment with EE-drospirenone-levomefolate calcium.

---

**Table 1** Baseline and demographic characteristics of study participants (per protocol set)

<table>
<thead>
<tr>
<th></th>
<th>EE-drsp-levomefolate calcium (n = 75)</th>
<th>EE-drsp + folic acid (n = 75)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>28.2 ± 5.7</td>
<td>27.0 ± 5.5</td>
</tr>
<tr>
<td>Height, cm</td>
<td>165.9 ± 6.3</td>
<td>167.1 ± 5.5</td>
</tr>
<tr>
<td>Body weight, kg</td>
<td>63.3 ± 8.2</td>
<td>62.8 ± 8.6</td>
</tr>
<tr>
<td>Body mass index, kg/m²</td>
<td>23.0 ± 2.6</td>
<td>22.5 ± 2.6</td>
</tr>
<tr>
<td>Current smoker, n (%)</td>
<td>22 (29.3)</td>
<td>21 (28.0)</td>
</tr>
</tbody>
</table>

**Note:** Data are presented as the mean ± standard deviation unless otherwise stated.

**Abbreviations:** drsp, drospirenone; EE, ethinylestradiol.

---

**Table 2** Area under the folate concentration-time curve from time 0 (baseline) to week 24 (AUC\(_{(0–24\text{ weeks})}\)) for plasma and RBC folate (uncorrected and corrected for baseline folate concentrations) after administration of EE-drospirenone-levomefolate calcium or EE-drospirenone + folic acid for 24 weeks (invasion phase; per protocol set)

<table>
<thead>
<tr>
<th></th>
<th>Plasma folate AUC(_{(0–24\text{ weeks})}) (nmol week/L)</th>
<th>RBC folate AUC(_{(0–24\text{ weeks})}) (nmol week/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline-uncorrected</td>
<td>Baseline-corrected</td>
</tr>
<tr>
<td>EE-drsp-levomefolate calcium (n = 75)</td>
<td>1030 (24.0)</td>
<td>640 (29.0)</td>
</tr>
<tr>
<td>EE-dsp + folic acid (n = 75)</td>
<td>904 (22.3)</td>
<td>561 (32.7)</td>
</tr>
</tbody>
</table>

**Note:** Data presented as geometric mean (% geometric coefficient of variation).

**Abbreviation:** AUC, area under the concentration-time curve; drsp, drospirenone; EE, ethinylestradiol; RBC, red blood cell.
Figure 3 Concentration-time curves for plasma folate during 24 weeks of treatment with EE-drospirenone-levomefolate calcium or EE-drospirenone + folic acid (invasion phase) and during the 20-week period following cessation of treatment (elimination phase; per protocol set).

Notes: Vertical lines indicate the mean ± standard deviation. Values prior to week 0 represent the three pretreatment measurements that were used to calculate the mean median baseline value. Vertical dotted line indicates the cutoff between the two phases.

Abbreviations: drsp, drospirenone; EE, ethinylestradiol.

Figure 4 Concentration-time curves for RBC folate during 24 weeks of treatment with EE-drospirenone-levomefolate calcium or EE-drospirenone + folic acid (invasion phase) and during the 20-week period following cessation of treatment (elimination phase; per protocol set).

Notes: Vertical lines indicate the mean ± standard deviation. Values prior to week 0 represent the three pre-treatment measurements that were used to calculate the mean median baseline value. Vertical dotted line indicates the cutoff between the two phases.

Abbreviations: drsp, drospirenone; EE, ethinylestradiol; RBC, red blood cell.
Elimination phase
The mean concentration-time curves for plasma and RBC folate during the elimination phase were comparable between groups (Figures 3 and 4). Plasma folate levels decreased at similar rates in both groups during the elimination phase, with approximately 40% of women in both groups maintaining plasma folate levels above those at baseline 20 weeks after the cessation of folate treatment (Table 3). Mean plasma folate values were $17.2 \pm 9.8 \text{ nmol/L}$ on day 28 of the fifth treatment cycle after cessation of treatment (ie, week 44) in the EE-drospirenone-levomefolate calcium group. For the EE-drospirenone + folic acid group, mean plasma folate concentrations were $14.7 \pm 6.2 \text{ nmol/L}$ at day 28 of cycle 5.

The median time to RBC folate concentrations falling below 906 nmol/L was 10 weeks (95% CI 8–12 weeks) after cessation of EE-drospirenone-levomefolate calcium treatment (ie, week 34 of the study; Figure 5). Although RBC folate levels decreased during the elimination phase in both groups of women, these levels remained above baseline for the majority (approximately 90% of women) at 20 weeks following cessation of folate treatment (Table 3). Four weeks after stopping folate intake, 85% of women maintained an RBC folate level above 906 nmol/L, the level associated with very low risk of neural tube defects. At 8, 10, 12, and 20 weeks after cessation of folate intake, the proportions of women with an RBC folate level above 906 nmol/L were 60%, 47%, 29%, and 9%, respectively. Mean RBC folate values at week 44, ie, 20 weeks after cessation of treatment, were $739.8 \pm 197.6 \text{ nmol/L}$ and $701.1 \pm 170.6 \text{ nmol/L}$ for the EE-drospirenone-levomefolate calcium and EE-drospirenone + folic acid groups, respectively.

Homocysteine levels
Invasion phase
Homocysteine values decreased from baseline (Table 3), reaching a plateau after 8 weeks in both treatment groups and remained below baseline values during the entire folate administration period of 24 weeks. At the end of the invasion phase (week 24), the mean homocysteine values were $7.5 \pm 1.6 \text{ µmol/L}$ and $7.6 \pm 1.4 \text{ µmol/L}$, respectively, for EE-drospirenone-levomefolate calcium and EE-drospirenone + folic acid.

Elimination phase
Homocysteine levels began to increase following cessation of folate treatment. By week 44 of the elimination phase, homocysteine levels remained below baseline in 34.7% of women in the EE-drospirenone-levomefolate calcium group and 40.0% of women in the EE-drospirenone + folic acid group (Table 3). Mean homocysteine levels at week 44 were $9.0 \pm 2.6$ for EE-drospirenone-levomefolate calcium and $8.9 \pm 1.9$ for EE-drospirenone + folic acid.

Folate metabolite pattern

While plasma L-5-methyl-THF could be determined in all samples analyzed, most of the concentrations for the other plasma folate metabolites were found to be below the lower level of quantification. As for total folate, the concentrations of L-5-methyl-THF in plasma were comparable between both treatment groups, with an almost completely overlapping range of values (Figure 6). For 5,10-methenyl-THF and THF, concentrations above the

### Table 3

<table>
<thead>
<tr>
<th>Week</th>
<th>Plasma folate</th>
<th>RBC folate</th>
<th>Homocysteine</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Levomefolate calcium</td>
<td>Folic acid</td>
<td>Levomefolate calcium</td>
</tr>
<tr>
<td>26</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td>4 (5.3)</td>
</tr>
<tr>
<td>28</td>
<td>4 (5.3)</td>
<td>4 (5.3)</td>
<td>8 (10.7)</td>
</tr>
<tr>
<td>30</td>
<td>5 (6.7)</td>
<td>8 (10.7)</td>
<td>11 (14.7)</td>
</tr>
<tr>
<td>32</td>
<td>11 (14.7)</td>
<td>12 (16.0)</td>
<td>14 (18.7)</td>
</tr>
<tr>
<td>34</td>
<td>15 (20.0)</td>
<td>17 (22.7)</td>
<td>16 (21.3)</td>
</tr>
<tr>
<td>36</td>
<td>23 (30.7)</td>
<td>23 (30.7)</td>
<td>19 (25.3)</td>
</tr>
<tr>
<td>38</td>
<td>25 (33.3)</td>
<td>25 (33.3)</td>
<td>20 (26.7)</td>
</tr>
<tr>
<td>40</td>
<td>30 (40.0)</td>
<td>34 (45.3)</td>
<td>22 (29.3)</td>
</tr>
<tr>
<td>42</td>
<td>30 (40.0)</td>
<td>38 (50.7)</td>
<td>25 (33.3)</td>
</tr>
<tr>
<td>44</td>
<td>44 (58.7)</td>
<td>45 (60.0)</td>
<td>26 (34.7)</td>
</tr>
</tbody>
</table>

**Notes:** Data are n (%). The mean median baseline values were as follows for EE-drospirenone-levomefolate calcium and EE-drospirenone + folic acid, respectively: plasma folate, 16.4 and 14.1 nmol/L; RBC folate, 78.3 and 550.2 nmol/L; homocysteine, 9.3 and 9.2 µmol/L.

**Abbreviations:** EE, ethinylestradiol; RBC, red blood cells.
Figure 5 Kaplan–Meier estimates for time to RBC folate levels falling below 906 nmol/L for EE-drospirenone following treatment with EE-drospirenone-levomefolate calcium (per protocol set).

Abbreviations: EE, ethinylestradiol; RBC, red blood cell.

lower level of quantification were noted in plasma in some women (Table 4). Comparison of treatment groups did not reveal differences with regard to either the metabolite concentrations above the lower level of quantification or the percentage of women with metabolite concentrations below the lower level of quantification (Figure 7) following daily intake of equimolar doses of levomefolate calcium or folic acid.

Figure 6 Distribution of individual L-MTHF plasma concentrations [nmol/L] at baseline (visit 1), week 12 (visit 8), and week 24 (visit 14) after daily oral administration of EE-drospirenone-levomefolate calcium (MTHF) or EE-drospirenone + FA.

Note: Lower level of quantification for L-MTHF was between 3.325 and 3.680 nmol/L.

Abbreviations: EE, ethinylestradiol; FA, folic acid; L-MTHF, L-5-methyl-tetrahydrofolate.
Table 4 Mean metabolite concentrations in plasma (nmol/L)

<table>
<thead>
<tr>
<th></th>
<th>EE-drsp-levomefolate calcium</th>
<th></th>
<th>EE-drsp + folic acid</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>THF</td>
<td>5,10-methenyl-THF</td>
<td>THF</td>
<td>5,10-methenyl-THF</td>
</tr>
<tr>
<td>Baseline</td>
<td>4.07 ± 0.357 (n = 4)</td>
<td>1.57 ± 0.412 (n = 9)</td>
<td>4.60 ± 0.656 (n = 7)</td>
<td>1.63 ± 0.372 (n = 8)</td>
</tr>
<tr>
<td>Week 12</td>
<td>4.98 ± 1.851 (n = 13)</td>
<td>1.76 ± 0.603 (n = 7)</td>
<td>5.28 ± 1.806 (n = 14)</td>
<td>1.45 ± 0.282 (n = 7)</td>
</tr>
<tr>
<td>Week 24</td>
<td>5.92 ± 2.318 (n = 23)</td>
<td>1.46 ± 0.238 (n = 12)</td>
<td>5.76 ± 2.835 (n = 19)</td>
<td>1.95 ± 1.166 (n = 12)</td>
</tr>
</tbody>
</table>

Notes: Values are presented as the mean ± standard deviation. Lower level of quantification = THF, between 3.447 and 3.539 nmol/L; 5,10-methenyl-THF, between 1.052 and 1.284 nmol/L.

Abbreviations: drsp, drospirenone; EE, ethinylestradiol; THF, tetrahydrofolate.

Pregnancies

Two pregnancies occurred during the study. One volunteer became pregnant before the start of treatment (i.e., during the screening period). This volunteer was not included in the study and delivered a healthy female at term. The second volunteer had a positive human chorionic gonadotropin test during the follow-up examination. A chemically-induced abortion was performed for social reasons. An ultrasound assessment in early pregnancy suggested that the volunteer became pregnant during intake of study medication in the elimination phase. A possible reason for this was an episode of diarrhea lasting 3 days approximately 2 weeks before the calculated date of conception (as determined by ultrasound).

Safety

The incidence of adverse events was similar between the EE-drospirenone-levomefolate calcium and EE-drospirenone + folic acid groups during the invasion phase and the elimination phase (Table 5). During the invasion phase, among the adverse events that were deemed possibly or probably related to the study medication, the most common were reproductive system and breast disorders (11 women [12.8%] and eight women [9.3%, respectively] and gastrointestinal disorders (six women [7.0%] receiving EE-drospirenone-levomefolate calcium and none of the women receiving EE-drospirenone + folic acid). There were four serious adverse events (acoustic neuroma and impaired wound healing after surgery [n = 1] in the EE-drospirenone-levomefolate calcium group;
Table 5  Adverse events during the invasion phase, elimination phase, and the overall study (invasion + elimination phase)

<table>
<thead>
<tr>
<th>Treatment during invasion phase</th>
<th>EE-drsp-levomefolate calcium</th>
<th>EE-drsp + folic acid</th>
</tr>
</thead>
<tbody>
<tr>
<td>Invasion phase</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AEs, %</td>
<td>96.5</td>
<td>95.3</td>
</tr>
<tr>
<td>TEAEs, %</td>
<td>30.2</td>
<td>15.1</td>
</tr>
<tr>
<td>SAEs, n</td>
<td>2 in 1 woman</td>
<td>2 in 2 women</td>
</tr>
<tr>
<td>Elimination phase</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AEs, %</td>
<td>87.5</td>
<td>91.5</td>
</tr>
<tr>
<td>TEAEs, %</td>
<td>8.8</td>
<td>11.0</td>
</tr>
<tr>
<td>SAEs, n</td>
<td>9 in 5 women</td>
<td>3 in 1 woman</td>
</tr>
</tbody>
</table>

Abbreviations: AE, adverse event; drsp, drospirenone; EE, ethinylestradiol; SAE, serious AE; TEAE, treatment-emergent AE.

During the elimination phase, the most common treatment-related adverse events in the EE-drspirenone-levomefolate calcium group were “psychiatric disorders”, occurring in 3.8% of women. In the EE-drspirenone + folic acid group, “reproductive system and breast disorders” were the most common treatment-related adverse events (7.3%). The most common of these were “breast discomfort” and similar terms (eg, pain, swelling, tenderness), “metrorrhagia” and similar terms, and “dysmenorrhea”. Nine serious adverse events occurred in five women in the EE-drspirenone-levomefolate calcium group (arthralgia, esophageal food impaction, appendicitis, abdominal pain lower, hemorrhagic ovarian cyst, abdominal pain, nausea, diarrhea, cholelithiasis). In the EE-drspirenone + folic acid group, three serious adverse events occurred in one woman (loss of consciousness, hyperventilation, alcohol poisoning). All serious adverse events were single occurrences and assessed as being unrelated to the study medication. General physical and gynecologic examinations as well as routine laboratory safety assessments did not give rise to any safety concerns.

Discussion

The invasion phase of this randomized, long-term study demonstrates that levomefolate calcium is a suitable alternative to folic acid for improving folate status when combined with an oral contraceptive in women of childbearing potential. This supports the concept that oral contraceptives represent a reasonable delivery vehicle for folate supplementation prior to pregnancy. Our results may be generalizable to other oral contraceptives, provided absence of interaction can be proven for the active components. The elimination phase of this study shows that 20 weeks after cessation of folate intake, an improved folate status is maintained in a large proportion of women.

Findings from the invasion phase, which are based on established surrogate parameters of folate status (plasma folate, RBC folate, and homocysteine), are consistent with two previous studies investigating the effects of levomefolate calcium and folic acid on folate levels in women of childbearing age. Data from a similarly designed study show that levomefolate calcium 0.451 mg/day (equimolar to 0.416 mg L-5-methyl-THF) and folic acid 0.400 mg/day increased plasma folate concentrations to a comparable extent after 24 weeks. This randomized, controlled study involving 144 women of childbearing age found that administration of levomefolate calcium 0.451 mg/day was more effective than folic acid 0.400 mg/day at improving folate status. In addition, as outlined above, the advantages of levomefolate calcium over folic acid are described in the literature.

Results from the elimination phase of this study are consistent with earlier, exploratory studies examining the change in folate status following cessation of folate supplementation. Hao et al examined the effect of 6 months of supplementation with oral folic acid (dose range 0.1–4 mg/day) in 1108 Chinese women. At the end of the observation period of 3 months after cessation of supplementation, plasma and RBC folate levels remained higher than baseline, and homocysteine levels remained lower than baseline. In another study of 27 healthy women receiving 0.500 mg folic acid/day for 8 weeks, plasma folate levels remained marginally above baseline and RBC folate levels clearly above baseline at the end of the observation period (12 weeks after cessation of supplementation).

After 24 weeks of treatment with EE-drspirenone-levomefolate calcium or EE-drspirenone + folic acid during the invasion phase of this study, the geometric mean AUC(0-24 weeks) was generally comparable for plasma and RBC folate. Using bioequivalence criteria for comparisons, exposure was shown to be similar between the treatment groups for the plasma folate baseline-uncorrected and baseline-corrected values and for RBC folate baseline-uncorrected values.

Based on single-dose data with EE-drspirenone-levomefolate calcium and levomefolate calcium and folic acid, accumulation of plasma folate as observed in the current study would not be predicted after daily dosing because folate levels returned to baseline within a 24-hour dosing interval. Thus, the observed increase in plasma folate suggests a dynamic equilibrium between tissue and plasma, in which tissue folate stores build up over time with treatment. As tissue folate levels increase, the distribution of...
folate into plasma changes, which leads to increased plasma concentrations. After cessation of daily folate intake, plasma folate levels decline gradually and much more slowly than after single oral folate administration. This slow decrease is attributed in part to a re-equilibration between plasma and tissue, indicating a slow release of folate from tissue stores into the plasma. Although plasma folate concentrations during the elimination phase were mainly determined by distribution and elimination processes, RBC folate concentrations followed a different time course, indicating a different underlying mechanism. Indeed, in the present study, RBC folate levels were maintained at ≥ 906 nmol/L for a further 10 weeks (ie, week 34 of the study) in 50% of the subjects after discontinuation of EE-drospirenone-levomefolate calcium. When the proportion of patients with folate levels above baseline was examined, RBC folate levels were maintained above baseline for 20 weeks (ie, five cycles) after cessation of EE-drospirenone-levomefolate calcium in 89.3% of women.

Following oral administration, folic acid is absorbed in the proximal small intestine, metabolized during passage across the intestinal mucosa and into the liver and enters the peripheral circulation as L-5-methyl-THF. Orally administered L-5-methyl-THF enters the systemic circulation as such. Therefore, any difference between folic acid and L-5-methyl-THF is expected to disappear as soon as folates enter the systemic circulation and enter the subsequent steps of metabolism. Based on this knowledge, oral administration of folic acid or L-5-methyl-THF would be expected to result in similar folate metabolite patterns in plasma. In the current study, all folate metabolites showed a qualitatively similar pattern between EE-drospirenone-levomefolate calcium and EE-drospirenone + folic acid at all time points throughout the invasion phase.

Elevated homocysteine concentrations have been shown to be a risk factor for low birth weight, premature delivery, pre-eclampsia, and neural tube defects. Previous studies have shown that levomefolate calcium is as effective as an equimolar dose of folic acid at lowering homocysteine concentrations. In agreement, the homocysteine-lowering effects of EE-drospirenone-levomefolate calcium and EE-drospirenone + folic acid were similar throughout the course of the invasion phase in this study.

In terms of timing of folate intake, this and several other studies have shown that it takes months to achieve steady-state plasma and RBC folate concentrations. The time point at which plasma folate levels reach a plateau seems to depend on baseline folate levels and sampling intervals, but the data suggest that a minimum of 8 weeks of treatment is needed in order to achieve steady-state concentrations. In a randomized controlled trial in a US population (in which baseline folate levels are higher due to mandatory food fortification), plasma folate levels reached a plateau after 8 weeks of treatment with EE 0.02 mg – drospirenone 3 mg – levomefolate calcium 0.451 mg. In other populations without mandatory food folate fortification, plasma folate levels reached a plateau after 12 weeks of treatment with folic acid or levomefolate calcium. Data on RBC folate levels indicate that a plateau is approached, but not completely reached, after 24 weeks of regular intake of folate supplements in populations without mandatory food folate fortification, a finding that is corroborated by the current study. Fetal neural tube defects occur early in pregnancy, within 28 days of conception, and the neural tube defect risk is directly linked to maternal folate status in the periconceptional period. Therefore, in order for a woman to maximize the reduction in neural tube defect risk, continuous folate intake needs to start well in advance of conception. Indeed, based on the results of long-term folate studies, Lamers et al recommended extending the period of periconceptional folic acid supplementation from 4 weeks to ≥ 12 weeks to achieve maximal risk reduction. The results of the current study support this recommendation.

The addition of folate to an oral contraceptive represents a valuable means of boosting folate levels in women of reproductive age who unintentionally conceive during use of oral contraception or cease use of oral contraceptives in order to become pregnant. A prospective, post-marketing, non-interventional cohort study of new oral contraceptive users in clinical practice across seven European countries showed that those who discontinue use of oral contraception to become pregnant, over one-fifth did so within one cycle after cessation of oral contraceptives and almost 50% after three cycles. The oral contraceptive plus folate combination represents a targeted approach to improve folate status specifically in women of childbearing potential.

During the elimination phase, a substantial proportion of women maintained folate levels that were higher than those at baseline, thus contributing to the reduction in neural tube defect risk. However, it is important that women who stop using a folate-containing oral contraceptive with the intention of becoming pregnant continue to receive adequate doses of folate. Indeed, the prescription of a folate-fortified oral contraceptive provides health care professionals with an opportunity to counsel women about the immediate need for adequate prenatal care following cessation of oral contraception.

All treatments were well tolerated, with no relevant differences observed between the groups. No serious adverse
events were considered to be treatment-related and the tolerability profiles of EE-drospirenone-levomefolate calcium and EE-drospirenone + folic acid during the invasion phase were consistent with those of other oral contraceptives. Overall, these results confirm that addition of folate to an oral contraceptive does not give rise to additional safety concerns.

In summary, treatment with EE-drospirenone-levomefolate calcium for 24 weeks resulted in similar rates of increase and, following cessation of treatment, in similar rates of decrease in plasma and RBC folate levels compared with treatment using EE-drospirenone + folic acid. The effect on plasma homocysteine levels was also comparable between the two treatments. In a substantial proportion of women, folate levels remained above those at baseline for five oral contraceptive treatment cycles following cessation of 24 weeks of daily treatment with EE-drospirenone-levomefolate calcium. The risk of a neural tube defect-affected pregnancy would be reduced in women with improved folate status compared with their risk prior to the start of folate treatment.

Acknowledgments

Funding for this study was provided by Bayer HealthCare Pharmaceuticals, the manufacturer of EE 0.030 mg--drospirenone 3 mg (Yasmin®) and EE-drospirenone-levomefolate calcium. The authors are grateful to Klaus Pietrzik for his stimulating discussions concerning the study design. The authors would also like to thank Guenter Michl (bioanalytics), Susanne Reschke (clinical pharmacokinetics), and Vijay Chauhan (clinical statistics).

Disclosure

The authors would like to thank Claire Byrne of inScience Communications, Springer Healthcare, for medical writing support during preparation of the manuscript, which was funded by Bayer HealthCare Pharmaceuticals. KD, DT, FE, BR, and HB are employees of Bayer HealthCare Pharmaceuticals. ML and MK are employees of Nuvisan GmbH, Neu-Ulm, Germany.

References


